We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+26.39%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$298M
AUM Growth
+$60.5M
Cap. Flow
+$29.8M
Cap. Flow %
9.99%
Top 10 Hldgs %
86.08%
Holding
25
New
6
Increased
9
Reduced
7
Closed
3

Top Buys

1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$24.1M
2
MXCT icon
MaxCyte
MXCT
+$12M
3
ATYR
aTyr Pharma
ATYR
+$10.6M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$8.31M
5
XOMA
Xoma
XOMA
+$5.33M

Top Sells

1
APEN
Apollo Endosurgery, Inc.
APEN
+$33.2M
2
URGN icon
UroGen Pharma
URGN
+$5.55M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$3.2M
4
EOLS icon
Evolus
EOLS
+$2.31M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$2.12M

Sector Composition

1 Healthcare 99.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$91.5M 30.7%
6,278,085
-55,154
-0.9% -$779K
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$30.2M 10.14%
782,289
+587,453
+302% +$24.1M
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$27.4M 9.21%
6,535,674
+1,601,574
+32% +$8.31M
ADMA icon
4
ADMA Biologics
ADMA
$2.02B
$25.4M 8.51%
7,661,690
+721,690
+10% +$2.49M
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$24.9M 8.34%
279,081
-20,919
-7% -$1.82M
XERS icon
6
Xeris Biopharma Holdings
XERS
$1.52B
$14.1M 4.72%
8,640,205
-2,554,984
-23% -$3.2M
MXCT icon
7
MaxCyte
MXCT
$133M
$13.4M 4.49%
2,707,090
+2,433,803
+891% +$12M
THRD
8
DELISTED
Third Harmonic Bio
THRD
$12.9M 4.33%
3,131,995
+1,116,694
+55% +$4.74M
ATYR
9
aTyr Pharma
ATYR
$50M
$10.1M 3.4%
+4,825,722
New +$10.6M
XOMA
10
DELISTED
Xoma
XOMA
$6.72M 2.25%
318,096
+253,637
+393% +$5.33M
CSTL icon
11
Castle Biosciences
CSTL
$733M
$6.65M 2.23%
292,866
+114,626
+64% +$2.8M
URGN icon
12
UroGen Pharma
URGN
$1.96B
$6.48M 2.17%
701,535
-603,412
-46% -$5.55M
RZLT icon
13
Rezolute
RZLT
$444M
$5.93M 1.99%
3,087,649
+66,145
+2% +$149K
EOLS icon
14
Evolus
EOLS
$377M
$4.9M 1.64%
578,795
-255,637
-31% -$2.31M
DVAX
15
DELISTED
Dynavax Technologies
DVAX
$4.09M 1.37%
+416,519
New +$4.45M
APEN
16
DELISTED
Apollo Endosurgery, Inc.
APEN
$3.67M 1.23%
370,000
-3,356,584
-90% -$33.2M
TVTX icon
17
Travere Therapeutics
TVTX
$5.27B
$2.97M 1%
+132,005
New +$2.81M
XGN icon
18
Exagen
XGN
$106M
$2.52M 0.85%
1,037,074
+183,032
+21% +$473K
AVIR icon
19
Atea Pharmaceuticals
AVIR
$390M
$2.29M 0.77%
+684,508
New +$2.78M
SCYX icon
20
SCYNEXIS
SCYX
$42.4M
$1.35M 0.45%
+56,250
New +$748K
CFMS
21
DELISTED
Conformis, Inc. Common Stock
CFMS
$648K 0.22%
402,651
-345,543
-46% -$743K
CDTX
22
DELISTED
Cidara Therapeutics
CDTX
$1.27K ﹤0.01%
+50
New +$1.42K
MIRM icon
23
Mirum Pharmaceuticals
MIRM
$7.25B
– –
-108,769
Closed -$2.12M
OABI icon
24
OmniAb
OABI
$307M
– –
-354,266
Closed -$1.28M
OPTN
25
DELISTED
OptiNose
OPTN
– –
-33,886
Closed -$940K

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Stonepine Capital Management held 25 positions worth $298M, up 25% from $238M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Stonepine Capital Management deployed $29.8M of net new capital in Q1 2023, opening 6 new positions and adding to 9 existing holdings. Its largest new stake was aTyr Pharma: 4,825,722 shares worth $10.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Apollo Endosurgery, Inc., an estimated $33.2M trimmed.

  • Stonepine Capital Management's largest Q1 2023 buy was aTyr Pharma: 4,825,722 shares worth $10.1M.
  • Stonepine Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q1 2023, an estimated $24.1M increase.
  • Stonepine Capital Management's biggest Q1 2023 reduction was Apollo Endosurgery, Inc., cutting an estimated $33.2M.
  • Stonepine Capital Management fully exited Mirum Pharmaceuticals in Q1 2023, selling an estimated $2.12M.
  • Stonepine Capital Management's ten largest holdings make up 86% of its $298M portfolio in Q1 2023.
  • Stonepine Capital Management opened 6 new positions and closed 3 in Q1 2023.
  • Stonepine Capital Management's portfolio value rose 25% quarter-over-quarter to $298M.

Based on Stonepine Capital Management's 13F filing for Q1 2023, filed 12 May 2023.